Insider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells 105,931 Shares Insider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells 105,931 Shares
Eliem Therapeutics EVP sells $338,000 in stock https://www.investing.com/news/company-news/eliem-therapeutics-evp-sells-338000-in-stock-93CH-3507674
RA Capital Management buys $49.95m of Eliem Therapeutics stock https://www.investing.com/news/company-news/ra-capital-management-buys-4995m-of-eliem-therapeutics-stock-93CH-3504716
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value No summary available.
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034. Two other large market indications that can be targeted using TNT119 are systemic lupus erythematosus and immune thrombocytopenia.
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® Indexes SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, as part of the annual reconstitution of the Russell stock indexes, effective today.
Eliem Therapeutics Expands Portfolio with Strategic Tenet Acquisition Eliem Therapeutics (ELYM) has issued an announcement. The Company recently completed its acquisition of Tenet, with the deal finalizing on June 27,…
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy
Eliem Therapeutics Announces Leadership Appointments Amidst Acquisition Moves The latest announcement is out from Eliem Therapeutics (ELYM). Aoife Brennan has been appointed as the President and CEO of Eliem, and will serve a…